Journal article

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4( )Foxp3(-) Cell-Mediated Modulation of CD103( ) Dendritic Cells

Paul A Beavis, Melissa A Henderson, Lauren Giuffrida, Alexander J Davenport, Emma V Petley, Imran G House, Junyun Lai, Kevin Sek, Nicole Milenkovski, Liza B John, Sherly Mardiana, Clare Y Slaney, Joseph A Trapani, Sherene Loi, Michael H Kershaw, Nicole M Haynes, Phillip K Darcy

CANCER IMMUNOLOGY RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2018

Abstract

Immunotherapy is widely accepted as a powerful new treatment modality for the treatment of cancer. The most successful form of immunotherapy to date has been the blockade of the immune checkpoints PD-1 and CTLA-4. Combining inhibitors of both PD-1 and CTLA-4 increases the proportion of patients who respond to immunotherapy. However, most patients still do not respond to checkpoint inhibitors, and prognostic biomarkers are currently lacking. Therefore, a better understanding of the mechanism by which these checkpoint inhibitors enhance antitumor immune responses is required to more accurately predict which patients are likely to respond and further enhance this treatment modality. Our current..

View full abstract

Grants

Awarded by National Health and Medical Research Council (NHMRC)


Awarded by Cancer Council Victoria


Awarded by National Breast Cancer Foundation


Awarded by NHMRC


Funding Acknowledgements

This work was funded by a Project and Program Grant from the National Health and Medical Research Council (NHMRC; grant number 1062580), a Cancer Council Victoria Project Grant (APP1084420), and a grant from the Peter MacCallum Cancer Centre Foundation. P.A. Beavis and C.Y. Slaney are supported by National Breast Cancer Foundation Fellowships (ID# ECF-17-005 and #ECF-16-005). P.K. Darcy and M.H. Kershaw are supported by NHMRC Senior Research Fellowships (APP1041828 and APP1058388, respectively).